Clinical trials - DiabetesontheNet

This site is intended for healthcare professionals only

Clinical trials

Filter:

Multiple Interventions for Diabetic Foot Ulcer Treatment (MIDFUT) trial: benefits of involvement for patients and clinicians

17 Nov 2020

ADA from home!

Practical messages for primary care practice from the American Diabetes Association's annual conference.

15 Jul 2020

News from the 2020 ADA conference

Breaking news stories from a primary care perspective.

1 Jul 2020

DAPA-CKD trial: Phase 3 stopped early after showing efficacy for CKD

AstraZeneca has announced that the phase 3 DAPA-CKD (Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease) trial will be stopped early following a recommendation from an independent data monitoring committee (DMC) based on its determination of overwhelming efficacy

30 Mar 2020

GLP-1 receptor agonists significantly improve CV outcomes

12 Dec 2019

GLP-1 receptor agonists have a wide range of benefits

12 Dec 2019

Canagliflozin effective in primary and secondary prevention of CV outcomes

12 Dec 2019

Diabetes Distilled: Controversial metformin recommendations in new ESC guidance

European guidance reflects new evidence on risk management in diabetes and pre-diabetes.

21 Nov 2019

Renoprotection for patients with diabetes and kidney disease

4 Oct 2019

Canagliflozin is cardioprotective in diabetic kidney disease

4 Oct 2019

Semaglutide reduces cardiovascular risk in type 2 diabetes

4 Oct 2019

Lowering LDL-cholesterol reduces CV event risk in diabetic dyslipidaemia

4 Oct 2019

Updates from the 2019 ADA meeting

News of the most important trial results for diabetes care from the 79^th Scientific Sessions of the American Diabetes Association.

6 Aug 2019

Renal trials, sex disparities in treatment, amputation and ADA nutrition guidelines

A round-up of the latest evidence and developments that will influence diabetes care.

7 May 2019

Editorial: Reducing the type 2 diabetes epidemic: Where can we make most impact?

Pam Brown, Editor-in-Chief, considers how primary care can best address the type 2 diabetes epidemic, and looks at new evidence from CREDENCE on preventing the progression of diabetic kidney disease.

7 May 2019

Canagliflozin provides renoprotection in type 2 diabetes with kidney disease

In this trial, investigators randomised patients with type 2 diabetes and kidney disease who had full renin–angiotensin–aldosterone system blockade to receive canagliflozin 100mg or placebo. Patients who took canagliflozin were 30% less likely than the placebo group to develop renal failure or die from either renal failure or cardiovascular disease. Their risk of renal failure or death fromrenal causes was reduced by 34%, and the risk of hospitalisation forheart failure or death due to cardiac causes decreased by 31%. Absolute risk reduction was 4.5%, translating into a number needed to treat of 22 over 2.5 years.

4 May 2019

Real-world evidence: improving quality in cardiometabolic medicine

A discussion of the strengths and limitations of real-world observational studies, plus an initiative to improve the availability of good quality, real-world evidence in cardiometabolic medicine.

3 May 2019

Studies that changed clinical practice: The management of lipids in diabetes: the key studies

How clinical studies on the effects of modifying blood lipids have shaped today’s clinical practice.

25 Feb 2019

Resources

For the latest news and articles

Resources

Journals

Useful information

;